Akebia Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
Portfolio Pulse from Benzinga Newsdesk
Akebia Therapeutics has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share, according to a formal notice from Nasdaq. The company's stock will continue to be listed and traded on the Nasdaq Capital Market.

May 22, 2023 | 9:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Akebia Therapeutics has regained compliance with Nasdaq's minimum bid price requirement, ensuring its stock will continue to be listed and traded on the Nasdaq Capital Market.
Akebia Therapeutics regaining compliance with Nasdaq's minimum bid price requirement is a positive development for the company, as it ensures its stock will continue to be listed and traded on the Nasdaq Capital Market. This news may boost investor confidence and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100